Trial Profile
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Inbakicept (Primary) ; Nivolumab (Primary) ; PD-L1-t-haNK (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms QUILT-3.055
- Sponsors Altor BioScience Corporation; ImmunityBio
- 25 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 25 Aug 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2024.
- 23 Aug 2021 Planned End Date changed from 1 Aug 2021 to 1 Dec 2023.